ML-323, 99%, a reversible, potent USP1-UAF1 inhibitor

Name: ML-323, 99%, a reversible, potent USP1-UAF1 inhibitor | 1572414-83-5
Brand: J&K Chemical
SKU: JK952639_5_MG
Price: 57.0 USD
Availability: InStock

Cat. No JK952639_5_MG

Vendor: J&K Chemical

Product Information

Product Name

ML-323, 99%, a reversible, potent USP1-UAF1 inhibitor

Brand Name

J&K

Product Number

952639

CAS

1572414-83-5

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

60167849

IUPAC Name

5-methyl-2-(2-propan-2-ylphenyl)-N-4-(triazol-1-yl)phenylmethylpyrimidin-4-amine

InChI Key

VUIRVWPJNKZOSS-UHFFFAOYSA-N

SMILES

CC1=CN=C(N=C1NCC2=CC=C(C=C2)N3C=CN=N3)C4=CC=CC=C4C(C)C

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2024-09-05

DOI: 10.1016/j.ejmech.2024.116568

Structural and Biochemical Insights into the Mechanism of Action of the Clinical USP1 Inhibitor, KSQ-4279

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2024-08-27

DOI: 10.1021/acs.jmedchem.4c01184

New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2024-07-02

DOI: 10.1021/acs.jmedchem.4c00113

Recent advances in the development of deubiquitinases inhibitors as antitumor agents

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2024-02-15

DOI: 10.1016/j.ejmech.2024.116161

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Publication Name: Science Translational Medicine

Publication Date: 2023-06-21

DOI: 10.1126/scitranslmed.add7872

ML-323, 99%, a reversible, potent USP1-UAF1 inhibitor

Product Information

General Information

Safety Information

References Data Source From Pubchem

Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors

Structural and Biochemical Insights into the Mechanism of Action of the Clinical USP1 Inhibitor, KSQ-4279

New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives

Recent advances in the development of deubiquitinases inhibitors as antitumor agents

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer